4 hours Akebia Therapeutics (NASDAQ:AKBA) Given “Buy” Rating at HC Wainwright MarketBeat
HC Wainwright reaffirmed a “buy” rating and issued a $7.50 price target on shares of Akebia Therapeutics in a research note on Tuesday.
HC Wainwright reaffirmed a “buy” rating and issued a $7.50 price target on shares of Akebia Therapeutics in a research note on Tuesday.